Kim Carla F
Stem Cell Program, Division of Hematology/Oncology and Division of Respiratory Disease, Boston Children's Hospital, Boston, MA, USA
Dept of Genetics, Harvard Medical School, Boston, MA, USA.
Eur Respir Rev. 2017 Jun 28;26(144). doi: 10.1183/16000617.0054-2017. Print 2017 Jun 30.
The use of stem cell biology approaches to study adult lung progenitor cells and lung cancer has brought a variety of new techniques to the field of lung biology and has elucidated new pathways that may be therapeutic targets in lung cancer. Recent results have begun to identify the ways in which different cell populations interact to regulate progenitor activity, and this has implications for the interventions that are possible in cancer and in a variety of lung diseases. Today's better understanding of the mechanisms that regulate lung progenitor cell self-renewal and differentiation, including understanding how multiple epigenetic factors affect lung injury repair, holds the promise for future better treatments for lung cancer and for optimising the response to therapy in lung cancer. Working between platforms in sophisticated organoid culture techniques, genetically engineered mouse models of injury and cancer, and human cell lines and specimens, lung progenitor cell studies can begin with basic biology, progress to translational research and finally lead to the beginnings of clinical trials.
利用干细胞生物学方法研究成人肺祖细胞和肺癌，为肺生物学领域带来了多种新技术，并阐明了可能成为肺癌治疗靶点的新途径。最近的研究结果已开始确定不同细胞群相互作用以调节祖细胞活性的方式，这对癌症和多种肺部疾病的可能干预措施具有启示意义。如今对调节肺祖细胞自我更新和分化机制的更好理解，包括了解多种表观遗传因素如何影响肺损伤修复，为未来更好地治疗肺癌以及优化肺癌治疗反应带来了希望。在复杂的类器官培养技术、损伤与癌症的基因工程小鼠模型以及人类细胞系和标本等平台之间开展研究，肺祖细胞研究可以从基础生物学入手，发展到转化研究，最终迈向临床试验的开端。
